WAVE Life Sciences Ltd WVE.OQ reported a quarterly adjusted loss of 30 cents per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of 17 cents. The mean expectation of sixteen analysts for the quarter was for a loss of 27 cents per share. Wall Street expected results to range from -35 cents to -11 cents per share.
Revenue fell 79.4% to $7.61 million from a year ago; analysts expected $16.30 million.
WAVE Life Sciences Ltd shares had fallen by 14.5% this quarter.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 2.2% in the last three months.
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG data February 26 at 02:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Dec. 31 2025 | -0.27 | -0.30 | Missed |
Jun. 30 2025 | -0.30 | -0.32 | Missed |
Jun. 30 2025 | -0.29 | -0.31 | Missed |
Mar. 31 2025 | -0.26 | -0.29 | Missed |
Comments